A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren’s Disease
CLN-978-SJ-101
Phase 1 other active
Quick answer
A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren’s Disease for Sjogren's Disease is a Phase 1 program (other) at Cullinan Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cullinan Therapeutics
- Indication
- Sjogren's Disease
- Phase
- Phase 1
- Modality
- other
- Status
- active